Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea

Trial Title: Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea

NCT ID: NCT05873231

Condition: Cancer

Conditions: Official terms:
Diarrhea

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Summary: The role of the gut microbiome in the development of side effects of anti cancer treatment will be assessed in this longitudinal cohort study.

Detailed description: Hepatocellular carcinoma (HCC) is the 5th most common tumor worldwide and the second most frequent cause of cancer-related death globally. HCC represents about 90% of primary liver cancers and constitutes a major global health problem.Therapeutic approaches depend on the stage of the disease. In the last decade systemic therapy approaches complement surgical and locoregional treatment in advanced disease stages. The current first-line drug class used to treat locally advanced and metastasized HCC are tyrosine kinase inhibitors (TKIs). At the moment the multikinase inhibitors sorafenib, lenvatinib and regorafenib are licensed in Austria for treatment of HCC: TKIs are a class of small molecule drugs that block the intracellular signals which drive proliferation in many malignant cells by specifically inhibiting the kinase function of individual intracellular pathways involved in receptor-mediated growth signaling.Diarrhea is one of the most common side effects of TKIs, that often prevents optimal dosage and thereby limits efficacy of systemic cancer therapy. Mechanisms of TKI induced diarrhea are largely unknown, speculations span from induction of exocrine pancreatic insufficiency leading to vitamin malabsorption and hypophosphatemia to enterocyte malfunction. Recently, accumulating data suggest that the composition of gut microbiome may also affect efficacy and toxicity of cancer therapy. In a small pilot study (n=25) patients who did not develop diarrhea under TKI had a higher abundance of Butyricimonas and a lower abundance of Citrobacter, Peptostreptococcus, and Staphylococcaceae. To the best of our knowledge, microbiome composition in patients with TKI induced diarrhea has not been studied in detail yet. However, this information is of clinical relevance since the manipulation of the gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation is an interesting strategy to improve efficacy and mitigate toxicity of anticancer drugs such as TKI. Probiotics for example have been shown to be able to prevent and treat diarrhea and may therefore be a valuable option to prevent or treat TKI-induced side effects. In 2019 around 5000 Austrian citizens were diagnosed with lung cancer. The diagnosis is associated with a very poor prognosis compared to other malignant diseases. However, the introduction of checkpoint inhibitors has led to a revolutionary improvement in prognosis for those that respond. Immune-Checkpoints are immunologic pathways that are used by tumor cells to evade destruction by immune cells. The most important checkpoints to date are programmed death ligand 1 (PDL-1), cytotoxic T lymphocyte antigen-4 (CTLA-4) and TIGIT. Antagonization of these check points by monoclonal antibodys can largely improve antineoplastic efficacy of immune cells. These immune checkpoint inhibitors (ICI) are essential part of modern neoadjuvant, adjuvant and palliative oncologic therapy concepts. ICI-treatment may lead to remarkable responses. However, 60 to 80 percent of patients do not respond to therapy.Although Tumor-PDL-1 level has shown some predictive value and is therefore used in clinical praxis it cannot predict response reliably. Many preclinical and clinical trials showed evidence of relevant impact of the composition of the microbiome of the gut and response to ICI. Therefore, the microbiome of the gut may be promising biomarker and even possible target for intervention to predict and improve ICI response in the future. However, the exact optimal composition of the gut microbiome and the strategies for intervention are still unclear.

Criteria for eligibility:

Study pop:
patients receiving systemic anti cancer therapy

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - 18 years or older - Start of a systemic anti-cancer therapy - Informed consent Exclusion Criteria: - • Pre-existing diarrhoea - Antibiotic therapy -4 to -1 week before inclusion - Probiotic treatment -4 to -1 week before inclusion - Inability to give informed consent

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Department of Internal Medicine, Medical University of Graz

Address:
City: Graz
Zip: 8010
Country: Austria

Status: Recruiting

Contact:
Last name: Vanessa Stadlbauer, MD

Phone: 0043316385

Phone ext: 82282
Email: vanessa.stadlbauer@medunigraz.at

Start date: April 28, 2021

Completion date: December 2032

Lead sponsor:
Agency: Medical University of Graz
Agency class: Other

Source: Medical University of Graz

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05873231